GLP-1 weight loss medications like Wegovy™ and Zepbound™ are in high demand, but their costs are straining employer budgets. With healthcare costs projected to rise by 8% in 2025, employers must find innovative ways to manage weight loss programs and control spending. In this session, Sal Morana, Pharmacy Benefits Lead at Alliant, will share insights on the clinical and financial benefits of investing in GLP-1 therapy. Dinesh Sheth, CEO and founder of GCL, will discuss a real-world case study where GCL partnered with a large employer of 100,000 retail workers to design a cost-effective, outcome-driven program. Learn how to implement weight management solutions that improve population health and how to structure your pharmacy benefits to offer impactful weight loss programs without exceeding your budget.

Key Takeaways

• Understand the importance of offering GLP-1 medications with therapy programs.
• How to drive sustainable outcomes for employees and families experience obesity, while lowering health costs over time.